Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people who take Wegovy for weight loss will need to continue it long term. Clinical evidence and NICE guidance both point in the same direction: semaglutide works while you take it, and for most people weight returns when treatment stops. That said, how long you should stay on it depends on how your body responds, your health goals, and a conversation with your prescriber. Wegovy (semaglutide 2.4 mg) is a prescription-only medicine, so any decision about duration is made with a clinician who knows your full picture, not from a fixed timetable.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
There is no universally fixed end date, and that surprises many people who expect a medicine to have a defined course. The honest answer is that Wegovy is treating an ongoing condition. Obesity is driven by biology (hormones, appetite signalling, metabolic set points) and semaglutide addresses those mechanisms while you take it. Remove the medicine and those same biological pressures return.
On the NHS, NICE's appraisal of semaglutide (TA875) does set a two-year maximum for prescribing within specialist weight management services, partly because longer NHS data and cost-effectiveness modelling were limited when the guidance was written. Privately, no equivalent ceiling exists in the licence, duration is a clinical decision made between you and your prescriber, revisited at every repeat review.
What both settings share is a six-month checkpoint. If you've been on the full maintenance dose for six months and have lost less than 5% of your starting body weight, guidance recommends reconsidering whether continuing makes sense. The timeline for Wegovy to show results varies person to person, but measurable progress within that window is a reasonable expectation.
So rather than asking "how many months is the course?" the better question is: is this still working for me, and is my prescriber reviewing that regularly? If you want a fuller answer to how long you should take Wegovy, including what the clinical evidence says about extended use, that page covers the topic in detail. At nume, a prescriber personally reviews every repeat order before it is dispensed.
The data here is stark, and it is worth knowing upfront rather than being caught off-guard. In the STEP 1 trial, published in the New England Journal of Medicine, participants who stopped semaglutide 2.4 mg after 68 weeks regained approximately two-thirds of the weight they had lost within 12 months of stopping. Hunger returned, appetite increased, and the metabolic adaptations the medicine had produced unwound relatively quickly.
This is not a failure of willpower or a fault with the medicine. It reflects the nature of obesity as a chronic condition, the same reason someone with high blood pressure takes medication indefinitely rather than stopping once their readings improve. Semaglutide manages the underlying biology; it doesn't permanently reset it.
If you're considering stopping, perhaps because of side effects, cost, or a sense that you've reached your goal, that conversation belongs with your prescriber. In some cases a structured pause is planned; in others, continuing at a lower dose may be an option worth discussing. The decision to come off Wegovy is rarely as simple as just stopping the pen.
A good prescriber looks at several things together: the weight you've lost, how you're tolerating the medicine, any weight-related conditions that prompted treatment in the first place (such as high blood pressure, sleep apnoea, or type 2 diabetes), and how your lifestyle changes are embedded alongside the treatment.
The NHS England guidance on weight management injections is clear that Wegovy should be used alongside (not instead of) dietary changes and increased physical activity. Where those habits are well established, stopping treatment is a different risk calculation than stopping when nothing else has changed.
Reviewing your treatment costs is part of this picture too. A realistic look at what Wegovy costs privately in the UK helps people plan for treatment that may be measured in years rather than months. At nume, there is no subscription and no auto-renewal; every order is re-reviewed clinically, which means the conversation about duration happens naturally rather than being buried in a rolling direct debit.
For a broader look at semaglutide duration questions, how long to take semaglutide covers related ground including the question of switching between forms. The short version: duration is personal, and that is exactly why it requires an ongoing clinical relationship, not a fixed rule.
Many people assume they can stop once they hit their goal. That is the most common misconception in this area, and it is completely understandable given how we think about most medicines. In practice, reaching a target weight is a milestone in treatment, not the end of it.
Whether continuing makes sense at that point depends on whether the conditions that made treatment appropriate in the first place have resolved or are being managed through other means. For some people, sustained lifestyle changes are sufficient after a period on treatment; for others, stopping triggers a return of the appetite dysregulation that drove weight gain in the first place. Your prescriber can help you distinguish between the two situations, and our guide to how long you should use Wegovy walks through the key factors to weigh up, ideally with a planned, supported wind-down rather than an abrupt stop.
Wegovy is now available in a higher 7.2 mg dose as well as the established 2.4 mg; some patients find a lower maintenance dose tolerable for the long term even if the titration schedule required higher doses initially. All of that is worked out as part of ongoing clinical review. If you're thinking about whether to continue, adjust, or stop, our prescribers are the right first call. You can explore your options and check your eligibility for a free consultation at any point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.